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Abstract
Background: Patients with Post kala-azar dermal leishmaniasis (PKDL) are considered a reservoir of Leishmania
donovani. It is imperative to identify and treat them early for control of visceral leishmaniasis (VL), a current priority
in the Indian subcontinent. We explored trends in clinico-epidemiological features of PKDL cases over last two
decades, for improving management of the disease.
Methods: Clinically suspected cases were diagnosed with rK39 strip test followed by parasitological confirmation
by microscopy and/or PCR/qPCR in skin tissue/slit aspirates. Patients were treated with antimonials till 2008 and
subsequently with miltefosine.
Results: The study indicated higher incidence of PKDL cases in areas of high endemicity for VL, with 20 % cases
reporting no history of VL. Approximately 26 % cases of PKDL were initially misdiagnosed at primary health centers.
Duration between onset of PKDL and diagnosis was above 12 months in 80 % cases. Diagnostic sensitivity was
32-36 % with microscopy and 96–100 % with PCR/qPCR. Compliance to treatment was over 85 % with miltefosine
while 15 % with antimonials. Relapse rate with miltefosine was up to 13.2 %.
Conclusions: PKDL patients tend to delay reporting and are often misdiagnosed. Confirmatory diagnosis using
minimally invasive skin slit aspirate samples would help overcome such issues. There was a paradigm shift in
compliance with miltefosine; however, increasing relapse rate indicated the need for newer therapies with oral
formulations.
Keywords: Diagnosis, Clinical Epidemiology, PKDL, Post kala-azar dermal leishmaniasis, Treatment, Visceral
Leishmaniasis, Bihar
Background
Leishmaniasis is an important parasitic disease, largely
affecting poorest of the poor in developing countries,
with over 350 million people worldwide considered at
risk to the disease [1]. The disease manifests in different
clinical forms, ranging from cutaneous leishmaniasis
(CL) to disfiguring mucosal lesions to the most severe
form, visceral leishmaniasis (VL). Currently, over 90 %
of annual incidence of VL occurs in countries like India,
Sudan, Bangladesh, Nepal, Brazil and Ethiopia [2]. Post
kala-azar dermal leishmaniasis (PKDL), a dermal sequel
of VL, is reported in areas endemic for Leishmania
donovani in the Indian subcontinent, Sudan and its ad-
joining areas [3, 4], although sporadic cases have been
reported from China, Japan, Iran and Iraq [5, 6]. In the
Indian subcontinent, up to 15 % of apparently cured VL
patients develop PKDL, as against 50–60 % in Sudan [3,
4, 7]. The disease is characterized by different clinical
presentations from simple hypo-pigmented macular
form to more developed lesions comprising of papular,
nodular cutaneous lesions and/or polymorphic forms
with mixed lesions. PKDL is not a life threatening
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disease, but more of a social stigma especially when
lesions present on the exposed parts of the body. Im-
portantly, in the Indian subcontinent, as the transmis-
sion of VL is anthroponotic, unattended cases of
active PKDL serve as durable reservoir of L. donovani
in VL endemic areas, especially during inter-epidemic
period [1]. Hence it calls for better management of
the disease. However, the clinical diagnosis of PKDL
still remains perplexing and often requires an experi-
enced clinician. Immunological diagnosis using rK39
strip test is not reliable for PKDL since antibodies
could be persisting due to past episode of VL. Con-
firmatory diagnosis with microscopy has limited sensi-
tivity and molecular techniques such as PCR/qPCR
are available only in limited centers.
For the past several decades, pentavalent antimonials
had been the first line treatment for management of VL
and amphotericin B deoxycholate and pentamidine
remained as second-line therapies. During 1980s, VL
cases from Bihar, India developed resistance to pentava-
lent antimonials and isolates of Leishmania were found
resistant to the drug [8, 9]. As a result, several formula-
tions such as amphotericin B, miltefosine and paromo-
mycin have been approved for treatment in the last
decade. Initially, it was considered that VL cases treated
with sodium antimony gluconate (SAG) may have higher
probability of developing PKDL [10], however, subse-
quently several cases of PKDL were reported following
VL treatment with other anti-leishmanial drugs includ-
ing miltefosine and amphotericin B [11, 12]. The num-
ber of cases following treatment with drugs other than
SAG may go up, as PKDL develops after several years of
cure from VL [13]. Therefore, a greater insight into
various clinical and epidemiologic aspects of PKDL is
warranted. The present study explored trends in clinical
and epidemiological features of PKDL cases over last
two decades in a tertiary hospital setting, constituting
the largest study undertaken so far in Indian PKDL, that
may have important implications for control of VL.
Methods
Study population
This is a hospital based retrospective study of PKDL
cases diagnosed over last two decades, between January
1995 to December 2014, at Department of Dermatology,
Safdarjung Hospital, New Delhi. A total of 282 cases
from Bihar and its adjoining states namely Eastern Uttar
Pradesh, West Bengal and Jharkhand, were registered.
Majority of them belonged to economically underprivil-
eged strata of society who migrated to Delhi for work
where they were seen in tertiary hospital settings.
Clinico-epidemiological details such as age, gender, na-
tivity, history of VL, age at the time of VL, drug taken
for VL treatment, history of PKDL and origins of PKDL
cases were recorded for each individual at the time of
reporting.
Diagnosis
All patients were clinically examined for the identifica-
tion of characteristic lesions such as macular, papular,
nodular or mixed/polymorphic forms. They were exam-
ined for skin sensation and subjected to analysis by dir-
ect microscopy in skin tissue/slit aspirates sample. In
later years, the cases were also subjected to rapid rK39
immuno-chromatographic strip test. Diagnosis was con-
firmed by demonstration of Leishmania amastigotes by
microscopy and/or demonstration of Leishmania DNA
with PCR/qPCR test as reported earlier [14, 15].
Categories of PKDL based on clinical presentation
Confirmed cases of PKDL were categorized into four
groups based on clinical presentation.
1. Macular PKDL: Cases presenting predominantly
with hypopigmented lesions.
2. Papulonodular PKDL: Cases presenting papular
and/or nodular lesions.
3. Mixed/polymorphic PKDL: Cases with all the three
type of lesions i.e. macular, papular and nodular.
4. Others: Cases with unusual presentations viz.
erythrodermic, fibroid type, plaque, ulcerated skin
lesions.
Treatment categories
1. Pre-miltefosine era: Majority of cases were treated
with SAG monotherapy, at the dose of 20 mg/kg/day
parenterally, either intramuscularly or intravenously,
not exceeding a total daily dose of 1 g (10 ml) for a
minimum period of 4 months or longer if necessary.
Additionally, combination therapy with SAG was
used in some cases. Four groups were formed in
which SAG was given along with either allopurinol
800 mg/day in divided doses, rifampicin 15 mg/kg, or
both allopurinol and rifampicin. Another group was
given Mw vaccine (Immuvac, Cadila Pharmaceuticals,
Ahmedabad, India), along with SAG, at the dose of
0.1 ml (containing heat-killed Mycobacterium
w 0.5 × 109 cells) intradermally at each site on
the first visit, and repeated every fortnight to a
total of five doses. The patients in all groups were
seen every fortnight for the first month and later
monthly, except those on vaccine therapy [16].
2. Miltefosine era: From 2009 onward, the cases were
treated with oral miltefosine, 50 mg thrice daily for
2 months or twice daily for 3 months for adults [17]
and 2.5 mg/kg/day for 3 months in children.
Pregnant or lactating women and patients with
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systemic ailments including HIV cases were excluded.
One case was exclusively treated with amphotericin B
(i.v. 50 mg/day, total dosage of 4.5 g), with strict
monitoring of renal functions [18]. The patients were
followed-up every 6 months up to 18 months,
whenever possible.
Ethics statement
All the patients were diagnosed and treated as per
the National Health Policy applicable at the time and
following the guidelines of the Ethical Committee,
VMMC & Safdarjung Hospital, New Delhi. The clinico-
epidemiological details of patients were collected main-
taining the confidentiality of the subjects under study.
Statistical analysis
The data were analyzed using SPSS software (version
19.0, SPSS, Inc., Chicago, IL, USA). The strength of as-
sociation between various variables and significance was
determined using chi-square (χ2) test. p values < 0.05
were considered as significant.
Results
PKDL predominant in areas of high endemicity for VL
A total of 282 PKDL cases (Male, n = 225, Female, n = 57)
were registered over last two decades since the year 1995
(Fig. 1). Majority (94.3 %, n = 266) of them originated from
Bihar, and the rest (5.7 %, n = 16) were from the adjoining
states namely Eastern Uttar Pradesh (3.5 %, n = 10), West
Bengal (1.4 %, n = 4) and Jharkhand (0.7 %, n = 2). VL
endemic areas in the state of Bihar have been cate-
gorised into high-, meso-, and low endemic areas
based on the presence of degree of antimony resist-
ance as reported earlier [19]. Adjoining states (Eastern
Uttar Pradesh, West Bengal and Jharkhand) were
categorised as low endemic region. Based on this clas-
sification, 63.5 % (n = 179) of PKDL cases originated from
high endemic area as against 30.1 % (n = 85) and
6.4 % (n = 18) from meso- and low-endemic areas re-
spectively (Fig. 1). We observed an upward trend in
reporting of PKDL cases to Safdarjung Hospital, New
Delhi, India since the year 2005 (Fig. 2).
Clinico-epidemiological characteristics
Our study recorded 79.8 % (n = 225) male and
20.2 % (n = 57) female with overall median age of
22 years (range 5–65 years). The median age of fe-
males (20 years, range = 8–60) was comparable to
that of males (22 years, range = 5–65, p = 0.789). Ma-
jority of cases belonged to the age group 19–44
years (64.5 %, n = 182), followed by paediatric cases
aged ≤ 18 years (30.1 %, n = 85) and the group aged ≥
45 years (5.3 %, n = 15).
Mixed/polymorphic form of lesions were predominant
in 53.5 % cases (n = 151) followed by macular lesions
(23.1 %, n = 65) and papulonodular lesions (21.6 %, n = 61).
Unusual clinical lesions such as erythrodermic, fibroid
type, plaque, ulcerated skin lesions were observed in
1.8 % (n = 5) cases. Polymorphic/mixed forms were
predominantly present in both genders (53.3 % males,
n = 120; 54.4 % females, n = 31) followed by papulo-
nodular form in males (24.9 %, n = 56) and macular
in females (36.8 %, n = 21). Papulonodular lesions
were the least frequent in female (8.8 %, n = 5) cases
whereas the macular lesions were the least frequent
in males (19.5 %, n = 44). The unusual clinical lesions
were exclusively observed in male cases (2.2 %, n = 5).
There was a significant association between type of
lesions and age (χ2 = 40.775 (6), p = 0.001), poly-
morphic/mixed lesions were predominant in adults
aged between 19–44 years. Furthermore, type of clin-
ical presentation were not associated with PKDL cases
by the area of origin (χ2 = 3.960(6), p = 0.682). Besides,
we observed mucosal lesions in 34 PKDL cases, all
males. Majority of them (n = 33) received SAG treat-
ment and one received amphotericin B treatment for
VL. Mucosal involvement showed no association with
lesion types (χ2 = 4.916(3), p = 0.178).
In the present study, 79.8 % (n = 225) of PKDL patients
reported history of VL. Among PKDL patients with his-
tory of VL, 52.9 % (n = 119) had mixed/polymorphic le-
sions, 24.9 % (n = 56) had only macular lesions and 20.9 %
(n = 47) had either papular and/or nodular. The remaining
1.3 % (n = 3) cases had unusual clinical presentations like
erythrodermic, fibroid or plaque. There was no association
between type of clinical presentation and history of VL
(χ2 = 2.289 (3) p = 0.515). In addition, there was an evi-
dence of association (χ2 = 9.681(2), p = 0.008) between
cases with history of VL and the place of origin, indicating
that the majority of the PKDL cases with history of VL
originated from high endemic zones. Overall, the median
time of manifestation of PKDL after VL treatment was
36 months (range = 1–384 months). PKDL lesions devel-
oped within 1 year in 13.3 % (n = 30), within 2–5 years in
56 % (n = 126) and after 5 years or more in 30.7 % (n = 69)
cases, after apparent cure from VL (Table 1). Majority of
cases with history of VL (93.3 %, n = 210) had been treated
for VL with SAG while the remaining were treated
with amphotericin B (5.3 %, n = 12) or miltefosine
(1.3 %, n = 3). The median time lapse after VL treat-
ment with SAG was 36 months (range, 1–384 months)
which was less compared with amphotericin B (48 months,
3.6 – 84 months) but more compared to miltefosine treat-
ment (21 months, range 12–36 months) (Table 2).
Besides, our data indicated that there was no asso-
ciation between type of drug used for VL treatment
and the time lapse between VL treatment and PKDL
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incidence (χ2 = 1.994 (2), p = 0.369). We observed signifi-
cant evidence of association (χ2 = 20.407(4), p < 0.001) be-
tween time lapse after VL treatment and age groups. The
data indicated that majority of cases belonging to age
group 19–44 yrs had onset of PKDL within 1–5 yrs
post VL treatment. However, endemicity (χ2 = 0.332(4),
p = 0.988) was independent of time lapse after VL treat-
ment and onset of PKDL.
Confirmatory diagnosis of PKDL based on minimally
invasive sampling
In the present study, the median time between appearance
of lesions and diagnosis was 30 months (range 1–240
months). Approx. 20.6 % (n = 57) of cases reported within
12 months and 54.9 % (n = 155) within 60 months after
the appearance of lesions. Diagnostic sensitivity of micros-
copy for the demonstration of Leishmania amastigotes in
two different samples such as tissue biopsy and skin slit
smear was compared. The Leishmania amastigotes were
evident in 31.5 % (89/282) tissue biopsy samples and in
Fig. 2 Incidence of PKDL in the reported period. Number of cases
reported to Safdarjung Hospital, New Delhi, India per five year block
duration since 1995
Fig. 1 Distribution of PKDL cases in Bihar and the adjoining states. Map showing the distribution of PKDL cases in the state of Bihar and
adjoining states, based on the area of high, moderate and low endemicity for VL, designated as per Sundar et al. [19]. Number shown in the
figure is the number of PKDL cases from the district
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36.2 % (107/282) slit aspirate samples. Diagnosis in cases
negative by microscopy was confirmed by PCR/qPCR. We
earlier demonstrated that rK39 strip test produced identi-
cal results with slit aspirate or serum as diagnostic sample
for PKDL [20]. Furthermore, we reported skin slit aspirate
as a good diagnostic specimen which offers sensitivity and
specificity comparable to that of tissue biopsy with qPCR
[20]. Therefore, we propose confirmatory diagnosis of
PKDL using minimally invasive skin slit aspirate samples
as described in Fig. 3.
Approximately, 26.95 % (n = 76) PKDL cases were ini-
tially misdiagnosed at primary health centers before they
reported to our center, of which, 77.63 % (n = 59) cases
had been misdiagnosed as cases of leprosy and received
either complete or partial treatment for the same. The
other misdiagnoses made were sarcoidosis in 11.84 %
(n = 9) cases, secondary syphilis in 3.94 % (n = 3), ros-
acea in 3.94 % (n = 3) and pityriasis versicolor in
2.63 % (n = 2) cases.
PKDL treatment
During the period from 1995 to 2008, a total of 59.57 %
(n = 168) cases were diagnosed for PKDL and treated
with SAG singly or in combination. Approximately
31.6 % (n = 89) PKDL cases were exclusively treated with
SAG, of which only 14.6 % (n = 13) patients completed
full treatment (Table 3). Combination of antimonials
with weak antileishmanial drugs like allopurinol, rifam-
picin, allopurinol and rifampicin, Mw (Immunvac) were
given in 79 cases. In the group receiving SAG with allo-
purinol (n = 56), only 17.8 % cases completed treatment
and achieved cure; the corresponding figure in the group
treated with SAG plus rifampicin group (n = 9) was
22.2 %. In SAG + rifampicin + allopurinol group (n = 6),
none could continue injections beyond 1½months. In
the group where Mw vaccine was combined with SAG
(n = 8), only 25 % adhered to complete treatment and
attained cure [16].
From 2009 onwards, a total of 113 patients were
treated either with miltefosine alone (n = 107) or in com-
bination with amphotericin B (n = 6). Of cases treated
exclusively with miltefosine, 85 % (n = 91) completed
treatment and achieved cure, while 14.9 % (n = 16)
remained absconded. In the 18 months follow up period,
we observed 13.2 % (n = 12) relapses (Table 3). Com-
bination of miltefosine along with amphotericin B was
given to 6 PKDL cases. One patient absconded and
the remaining 5 completed treatment and none re-
lapsed. One PKDL patient who was treated exclusively
with amphotericin B remained cured.
Discussion
This hospital based retrospective study over last two
decades brings forth some essential points on clinical
epidemiology of PKDL which would help establish ap-
propriate control measures for VL. As expected, major-
ity of PKDL cases originated from the area of high
endemicity for VL, which could be due to multiple fac-
tors such as specific climatic conditions, socio-economic
status, weak immune status, malnourishment [21]. There
was an upward trend in the number of PKDL cases
reporting to our center since the year 2005, probably
due to higher awareness and increasing number of refer-
rals to our center. With regard to clinical presentation,
majority of cases had mixed/polymorphic form followed
by macular and papulonodular lesions. Additionally, the
study indicated a significant association between types of
lesion with age, indicating that the polymorphic/mixed
lesions were predominant in adults aged between 19–44
years. Our study revealed that there was mucosal in-
volvement in 15 % cases, present across various lesion
types. Mucosal invasion in PKDL is relatively uncom-
mon and only sporadic cases have been reported [22]. A
limitation of the current report is the selection of study
population, that comprised mainly of migrants-for-work
from endemic areas for VL, who were understandably
predominantly males therefore gender based analysis
were avoided.
Nearly one fifth of PKDL cases reported no history of
VL. This could be because patients were either not
aware of it or had asymptomatic infection in the past.









No. of unusual clinical
presentations
Total No. (%) p
<1 9 3 18 0 30 (13.34) χ2 = 13.324 (6), p = 0.038
1–5 33 30 63 0 126 (56)
>5 13 15 38 3 69 (30.67)
Total No. (%) 55 (24.44) 48 (21.33) 119 (52.88) 3 (1.34) 225
Table 2 Time lapse between VL and PKDL with respect to the
drug used for VL treatment
Anti-leishmanial drug No. (%)
patients




SAG 210 (93.33) 36 1–384
Amphotericin B 12 (5.33) 48 3.6–84
Miltefosine 3 (1.33) 21 12–36
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Fig. 3 Diagnosis of PKDL based on minimally invasive sampling technique. The proposed flowchart for the confirmatory diagnosis of PKDL
Table 3 Outcome of treatment – compliance and relapse
Treatment No. (%) patients No. (%) of patients who completed treatment No. (%) of relapse
SAG 89 (31.56) 13 (14.61) -
SAG + Allopurinol 56 (19.86) 10 (17.85) -
SAG + Rifampicin 9 (3.19) 2 (22.23) Not followed
SAG + Allopurinol + Rifampicin 6 (2.12) 0 (0) -
SAG +Mw Vaccine 8 (2.83) 2 (25) -
Miltefosine 107 (37.94) 91 (85.05) 12 (13.18)
Amphotericin B 1 (0.35) 1 (100) -
Miltefosine + Amphotericin B 6 (2.12) 5 (83.33) -
Total 282 124 (43.97) 12 (9.67)
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The study revealed a significant association between
time lapse after VL and the age group, indicating that
cases in age group 19–44 year had onset of PKDL be-
tween 1–5 year following VL. However, the area of ori-
gin did not influence the time lapse between VL and
PKDL. Nearly 70 % of cases manifested PKDL within
5 year following cure from VL, similar to an earlier re-
port [12], however, this differs from the trend of PKDL
development in Sudan where majority of cases develop
lesions during VL or within the same year of VL treat-
ment [23].
The variability of clinical presentations, poor aware-
ness of this otherwise asymptomatic dermatosis, the mi-
gration of patients to non-endemic areas and lack of
laboratory facilities to confirm diagnosis remain the
major impediments in early recognition of PKDL [24].
In the present study, over 80 % cases were given a diag-
nosis after 12 months following first appearance of le-
sion, with overall median time lapse of 30 months. The
delay in reporting could be explained as the disease is
neither life threatening nor causing major discomfort
and is common in people who mainly depend on daily
wages for livelihood. Another reason for delayed diagnosis
is misdiagnosis of the disease at various primary health
centers, primarily as leprosy, a co-endemic dermatosis
with high prevalence in the same areas. The early, accur-
ate and feasible diagnosis of PKDL cases has been a long
term goal that has important implications in the VL con-
trol program. Our data indicated that sensitivity of dem-
onstration of Leishmania amastigotes by microscopy was
32 % to 36 % using slit smear or tissue biopsy, similar to
the report from Bangladesh [25]. However, the sensitivity
and specificity of molecular diagnostic methods such as
PCR/qPCR was very high [14, 15]. These molecular tests
gave equally reliable results using tissue sample or skin slit
aspirates [20] although they have limitations such as high
initial investment and high cost per test. We earlier dem-
onstrated that rK39 strip test produced identical results
with slit aspirate or serum as diagnostic sample for PKDL
[20]. Furthermore, we reported skin slit aspirate as a good
diagnostic specimen which offers sensitivity and specificity
comparable to that of tissue biopsy with qPCR [20].
Therefore, we propose confirmatory diagnosis of PKDL
using minimally invasive skin slit aspirate samples as de-
scribed in Fig. 3. This procedure would reduce discomfort
and permanent scarring and thus encourage patients to
come forward for timely diagnosis and monitoring post-
treatment.
During pre-miltefosine era, management of PKDL
remained a challenge in terms of clinical diagnosis and
treatment. In the present report, approximately one
third PKDL cases were exclusively treated with SAG, of
which only 14.6 % patients completed full treatment
regimen (Table 3). The high volume of antimonials given
parenterally, the long duration and the side effects could
be the major impediments to this recommended therapy.
Hence it was attempted to combine antimonials with
weak antileishmanial drugs like allopurinol, rifampicin,
allopurinol and rifampicin, Mw (Immunvac) to over-
come these issues. Even with the combined regimen,
duration of therapy with regular SAG injections did not
significantly alter and hence there was no noticeable
decrease in the overall dropout rate. Mw vaccine is de-
rived from a nonpathogenic, saprophytic, Mycobacter-
ium strain [26] and a chance observation of its efficacy
in PKDL in the mid-nineties [4], led us to try it along
with SAG. It is an immunomodulator for enhancing Th1
response of the host in many conditions. However, our
experience with Mw vaccine in containing PKDL was
less impressive. Similarly, Mw vaccine was also demon-
strated to be ineffective in controlling experimental VL
infection by L. donovani [27], contrary to its role in
managing tuberculosis and leprosy infections. We ob-
served that during pre-miltefosine era, over 85 % dropouts
in PKDL cases across various treatment regimens were re-
corded and these partially treated cases were the potential
reservoir of the Leishmania parasites especially in the en-
demic regions.
Another promising anti-leishmanial drug, amphoteri-
cin B also showed poor compliance since it required
hospitalization. In recent times, single dose of liposomal
form of amphotericin B such as Ambisome has been
shown to be highly effective against both VL and PKDL
[28–30]. Another antileishmanial drug, miltefosine was
introduced in India in 2002, for the treatment of VL and
was subsequently recommended for PKDL. This her-
alded the miltefosine era where the patients could take
the drug orally and get cured. It proved to be a giant
step in management of PKDL [31]. In the present report,
a total of 107 cases of PKDL were exclusively treated
with miltefosine, of which 85 % had successfully com-
pleted treatment regimen and achieved cure. In those
patients who remained regular, mucosal lesions were
the first to regress, followed by nodules while macular
lesions took the longest time to show improvement.
Initially, there were no relapses in one year follow-up
however, in recent years there were 13.2 % relapses at
18 months follow-up, probably due to increase in tol-
erance to miltefosine. Hence, attempts were made to
treat PKDL using combination of miltefosine and
amphotericin B in a small number of cases which led
to successful treatment. Similar to the antimony era
where Leishmania parasites showed gradual increase
in tolerance and resistance, miltefosine has also been
reported to exhibit similar behavior [32]. This calls
for formulations of newer and effective oral drugs
which can be used singly or in combination to com-
bat resistance.
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Conclusions
PKDL requires major attention for its proper manage-
ment and thus control of VL. This hospital based study
brings forth some essential points on trends in clinical
and epidemiological features of PKDL cases. Higher inci-
dence of PKDL was observed in areas of high endemicity
for VL. Importantly, majority of the patients tend to
delay reporting to primary health centers and are often
misdiagnosed. Confirmatory diagnosis based on minimally
invasive skin slit aspirate samples needs to be practised to
minimize discomfort and scarring, thus encouraging the
patients to come forward for early diagnosis as well as
follow up. Furthermore, there was a dramatic increase in
compliance with oral miltefosine treatment; however in-
creasing relapse rate in long term follow up warrants the
introduction of newer/combination therapies with oral
formulations.
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